<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="tbl1">
 <label>Table 1</label>
 <caption>
  <p>WHO Target Product Profile</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Variable</th>
    <th>Preferred profile</th>
    <th>Minimal profile</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>Indication for use</td>
    <td colspan="2">Prevent clinical illness in individuals ≥9 y</td>
   </tr>
   <tr>
    <td>Contraindications</td>
    <td colspan="2">None for pregnant/lactating women</td>
   </tr>
   <tr>
    <td>Target population</td>
    <td colspan="2">Women of reproductive age
     <break/>Adolescent girls ≥9 y
     <break/>Boys/men of the same age range
    </td>
   </tr>
   <tr>
    <td>Exclusions</td>
    <td colspan="2">Depends on vaccine platform:
     <break/>Neurologic disorders
     <break/>Autoimmune disorders
     <break/>Immunosuppression
    </td>
   </tr>
   <tr>
    <td>Vaccine type</td>
    <td>
     <list list-type="simple" id="olist0010">
      <list-item id="u0010">
       <p id="p0200">Nonreplicating platforms
        <list list-type="simple" id="ulist0010">
         <list-item id="u0015">
          <label>•</label>
          <p id="p0205">Inactivate whole virus</p>
         </list-item>
         <list-item id="u0020">
          <label>•</label>
          <p id="p0210">Subunit-based</p>
         </list-item>
        </list>
       </p>
      </list-item>
      <list-item id="u0025">
       <p id="p0215">Platforms with licensed vaccines</p>
      </list-item>
     </list>
    </td>
    <td>Single-cycle replicating vectors with robust safety data
     <break/>Live attenuated vaccine or replication competent with safety data
    </td>
   </tr>
   <tr>
    <td>Safety/reactogenicity</td>
    <td>Comparable to WHO-recommended vaccines
     <break/>Low risk of high fever
    </td>
    <td>Tolerable reactogenicity and acceptable safety profile</td>
   </tr>
   <tr>
    <td>Efficacy</td>
    <td>Demonstrated prevention of ZIKV illness</td>
    <td>Meets an established surrogate of immunity in animal models or cohort studies (ie, neutralizing Ab titers in &gt;70% of recipients)</td>
   </tr>
   <tr>
    <td>Dose</td>
    <td>Single dose</td>
    <td>Multiple dose</td>
   </tr>
   <tr>
    <td>Durability</td>
    <td>Long-lasting protection of more than 1 y and can be maintained by a single booster dose</td>
    <td>Protection lasts at least 1 y and can be maintained by booster doses</td>
   </tr>
   <tr>
    <td>Route</td>
    <td colspan="2">Injectable (IM or SC)</td>
   </tr>
   <tr>
    <td>Virus coverage</td>
    <td colspan="2">Monovalent with documented neutralization of Asian and African lineages</td>
   </tr>
   <tr>
    <td>Product stability</td>
    <td>At least 12 mo at −20°C
     <break/>At least 6 mo at 2°-8°C
    </td>
    <td>At least 12 mo at −20°C
     <break/>Stability for 6 h at 2°-8°C
    </td>
   </tr>
   <tr>
    <td>Coadministration with other vaccines</td>
    <td>Can be administered with other vaccines with no loss of immunogenicity or safety</td>
    <td>Stand-alone vaccine</td>
   </tr>
   <tr>
    <td>Presentation and packaging</td>
    <td>Liquid product in single-dose or multidose packages. Maximal volume of 0.5 mL</td>
    <td>Lyophilized product in single-dose or multidose packages. Maximal volume of 0.5 mL</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>Ab = antibody; IM = intramuscular; SC = subcutaneous; WHO = World Health Organization; ZIKV = Zika virus.</p>
  </fn>
 </table-wrap-foot>
 <attrib>Data from the World Health Organization.
  <xref rid="bib47" ref-type="bibr">
   <sup>47</sup>
  </xref>
 </attrib>
</table-wrap>
